Pharmaxis to raise further funds

By Renate Krelle
Tuesday, 02 November, 2004

Following its recent announcement of a successful Phase III trial of the successful completion of a Phase III clinical trial for its asthma diagnostic and treatment management tool Aridol, Sydney's Pharmaxis (ASX:PXS) has entered a trading halt -- to be lifted tomorrow morning -- pending the announcement of details of a placement and share purchase plan.

The company will conduct the placement via a bookbuild.

Related News

Cartherics and Catalent announce enhanced partnership

To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...

Alliance seeks to boost regional capacity in clinical trials

Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...

Lipid science receives new Australia-led online hub

The Lipid Network launched this month to build links between researchers, clinicians and industry...

Content from other channels on our network

Digital water treatment — real-time data for safe and efficient processes

Key insights from first mandatory sustainability reporting

Vessev launches an electric hydrofoiling network in Tas

Office tower cuts HVAC energy use by nearly 50%

Climate Tech Partners backs Australian battery recycling

Robots that can peel and slice curvy veggies

Flour mill expansion in Ballarat

A circular approach to food waste for chicken meat

Nestlé partners on nutrition research targeted for women's health

Next-gen pumps use film-based technology

Support at Home showering reclassified as 'clinical care' as part of $3bn investment

Victoria announces "massive" upgrade to one of its busiest hospitals

NSW IRC decision prompts "mixed emotions" from nurses and midwives

Surgical robot expands its scope of procedures

Neuroscientists propose clinical definition for brain fog in menopause

  • All content Copyright © 2026 Westwick-Farrow Pty Ltd